Satya Pharma and Alivexis Discover Best-in-Class PKMYT1 Inhibitor
Satya Pharma and Alivexis have successfully developed a highly selective and safe PKMYT1 inhibitor for CCNE-1 amplified and other biomarker-identified tumors.
Collaboration and Development
Satyarx Pharma Innovations Private Limited (“Satya Pharma”), an oncology biotech, and Alivexis, Inc., a global biotech company, entered into a preclinical collaboration in May 2023 to develop a best-in-class PKMYT1 inhibitor. Under the agreement, both companies co-funded and developed a pre-clinical candidate selectively targeting PKMYT-1 while sparing Wee1 and other related proteins.
Significance of PKMYT1 Inhibitors
PKMYT1 inhibitors are a novel class of therapeutics targeting CCNE1-amplified cancers, addressing a significant unmet medical need.
Expertise and Innovation
This collaboration utilized Alivexis’ Intelligent Supercomputing capabilities and the experienced drug discovery team at Satya. The developed candidate and backup compounds show excellent efficacy, improved safety, and a wide therapeutic window in preclinical studies, making them suitable for single or combination therapy.
Partnership Opportunities
The program, now part of the Alivexis portfolio (ALVX-A), is available for partnering.
About Satya Pharma
Founded in August 2020, Satya Pharma is an oncology biotech focused on DDR pathways and developing first-in-class therapeutics with novel binding mechanisms. Satya aims to discover drugs targeting critical biological pathways in oncogenesis or resistance mechanisms, presenting novel treatment opportunities.
About Alivexis
Alivexis, Inc. is a technology-driven drug discovery enterprise based in Japan and the U.S. It combines advanced drug discovery platforms, such as ModBind™ for accelerated simulation, with deep disease biology knowledge. Alivexis focuses on small molecule drugs and R&D collaborations for cancer, immune-inflammatory conditions, and rare diseases. Recently, Alivexis out-licensed its Cathepsin C clinical candidate to Melodia Therapeutics for up to 245 million USD.
Global Leadership
Managed by a team with extensive experience in Japan and the U.S., Alivexis follows a collaborative, network-based approach to drug discovery.
Leave A Comment